Type 1 diabetes (often referred to as childhood diabetes) is a
lifelong, autoimmune condition which impairs the body’s ability to
produce insulin. If left undiagnosed or untreated, excess glucose
causes damage to organs which can result in severe health
complications and, ultimately, in premature death. There is currently
no prevention or cure and the only effective long-term treatment is
multiple, daily injections of insulin.
Type 1 diabetes is one of the most common chronic childhood
illnesses. The International Diabetes Federation (IDF) estimates that
globally, more than 1.2 million young people under 20 years have type
1 diabetes and approximately 184,100 new cases are diagnosed each
year. However, in low-resource settings, children with type 1 diabetes
are often misdiagnosed or lack access to adequate healthcare services
to manage their condition.
Changing Diabetes® in Children was established in 2009 as a
public-private partnership to bridge these critical gaps in care. The
partnership provides comprehensive diabetes care for children and
youth living with type 1 in low- and middle-income countries. This
includes free life-saving insulin and other medical supplies for
persons up to 25 years of age.
Our ambition is clear: no child should die of diabetes. To learn
more about Changing Diabetes® in Children, click here.
As part of Novo Nordisk’s Defeat
Diabetes social responsibility strategy, Changing Diabetes® in
Children aims to reach 100,000 vulnerable children and young people
living with type 1 diabetes by 2030.
In 2021, 31,846 children were reached through Changing Diabetes® in
Children, a 13% increase compared to the previous year.
The partnership is present in 18 countries by the end of 2021,
following the addition of Ghana, Indonesia, Pakistan, and Peru during
the year. Five more countries (Jordan, Lebanon, Malawi, Mozambique and
Rwanda) are launching in early 2022 as part of an expanded partnership
project with the World Diabetes Foundation.